Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 19/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.68 |
| ▸ | HPGD | P15428 | 9/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | IDE | P14735 | 1/20 | 0.59 |
| ▸ | MPI | P34949 | 1/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485203 | 0.83 | KDM4E (0.65) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL31146266 | 0.83 | KDM4E (0.65) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL5313245 | 0.81 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDGAANPSR1 | |
| SCHEMBL10050059 | 0.80 | KDM4E (0.77) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL6703051 | 0.79 | GRIN2D (0.56) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31146027 | 0.79 | PIM1 (0.48) | KDM4EALDH1A1HPGDGAANPSR1 | |
| SCHEMBL4660869 | 0.78 | MAPT (0.60) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL114551 | 0.78 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDGAANPSR1 | |
| SCHEMBL30479099 | 0.78 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDGAANPSR1 | |
| SCHEMBL4468686 | 0.78 | KDM4E (0.68) | KDM4EALDH1A1HPGDGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224980-A1 | Substituted 1H-quinolin-2-one compounds | GRUNENTHAL GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| US-20040224980-A1 | Substituted 1H-quinolin-2-one compounds | GRUNENTHAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224980-A1 | Substituted 1H-quinolin-2-one compounds | NQO1, QARS1, QDPR | KDM4E 3634/4885ALDH1A1 1565/4885HPGD 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.